IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.
A 2026 guide to building an AI roadmap for biotech: data readiness, use-case sequencing, FDA/EMA and EU AI Act governance, talent, and 5 named case studies including Roche, Novo Nordisk, and Insilico Medicine.
A 2026 analyst comparison of biotech AI enablement programs versus one-time AI workshops, covering pricing bands from $2,500 to $250,000, named cases at J&J, AstraZeneca, Sanofi, and Moderna, and FDA/EU AI Act compliance implications.
A 2026 analyst guide to building an AI Center of Excellence in biotech: hub-spoke-hybrid models, FDA/EMA/NIST governance, staffing budgets from $2M to $200M, and named cases from Sanofi, Merck, Novartis, AstraZeneca, and GSK.
A 2026 data-driven benchmark of AI enablement in biotech covering adoption surveys, drug discovery market sizing, FDA/EMA guidance, and five real-world case studies including Insilico Medicine and Isomorphic Labs.
A 2026 analyst framework mapping biotech and pharma AI adoption across five maturity stages, from shadow AI use to autonomous agentic systems, with governance, GxP validation, and regulatory benchmarks.
A 2026 framework for biotech AI strategy: a five-axis prioritization matrix, FDA/EMA risk tiering, data readiness benchmarks, ROI data, and five named case studies including Insilico, Recursion, and Xaira.
Analyst report on AI in preclinical development in 2026: market size, FDA credibility framework and animal-testing roadmap, organ-on-chip adoption, and five named case studies.
© 2026 IntuitionLabs. All rights reserved.
